Magnesium sulphate or diltiazem addition to total intravenous anesthesia (TIVA) to reduce blood loss in Functional Endoscopic Sinus Surgery (FESS).

Magnesium sulphate or diltiazem as adjuvants to TIVA to reduce blood loss in Functional Endoscopic Sinus Surgery (FESS): A pilot study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/11/006391

Enrollment

Registered

2015-11-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- ASA I- II patients aged 18-60 years of either sex Health Condition 2: J324- Chronic pansinusitis

Interventions

Intervention1: Magnesium Sulphate (MgSO4): Vasodilator drug for controlled hypotension. Calcium antagonist and a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor Dose -40mg/kg bo

Eligibility

Inclusion criteria

Inclusion criteria: ASA I and II patients undergoing elective Functional Endoscopic Sinus Surgery (FESS)

Exclusion criteria

Exclusion criteria: coronary artery disease, previous myocardial infarction, stroke, CHF, arrhythmias, bleeding diathesis, uncontrolled systemic illness, anticipated difficult intubation, history of allergy to the study drugs, and patients who refused to participate

Design outcomes

Primary

Measure	Time frame
Total Blood lossTimepoint: End of surgery	—

Secondary

Measure	Time frame
HemodynamicsTimepoint: Intra-operative;Surgical fieldTimepoint: intra-operative	—

Countries

India

Contacts

Public ContactDr Ajisha Aravindan

All India Institute of Medical Sciences(AIIMS)

drsrajeshwari@gmail.com9810079229

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026